Amsterdam, Netherlands – The neoantigen field is having a pivotal year with a surge of new investments, collaborations and positive clinical readouts such as those by Nykode Therapeutics & Regeneron & Transgene & NEC’s. However, key challenges remain before they truly become blockbuster therapies for patients in need.
Building upon the momentum and progress in the field, such as the announcement of the first British patient to be receiving an mRNA-based cancer therapy, the 7th International Neoantigen Summit 2024 returns to Amsterdam to unite the international neoantigen community to overcome neoantigen identification, prediction, and translational challengesthat are holding back the full potential of this class of therapies.
Join leading neoantigen trailblazers from the likes of Gritstone Bio, CureVac, Medigene, Geneos Therapeutics & Nykode Therapeuticsat the only end to end, industry dedicated neoantigen meeting covering the depth and breadth of the field from mRNA- to DNA- and viral vector- based vaccinesas well as novel cell therapies with the true potentials to develop safe, durable and effective off-the-shelf or individualized neoantigen immunotherapeutics and vaccines for cancer patients.
For further details about the summit, including registration, please click here.
Summit at a glance
When: April 29 – May 1, 2024
Venue: Hotel Novotel Amsterdam City – Europaboulevard 10 – 1083 AD Amsterdam NL